HGS1029

DRUG2 trials

Sponsors

Human Genome Sciences Inc.

Conditions

Advanced Solid TumorsLymphoid Malignancies

Phase 1

A Study of HGS1029 (AEG40826-2HCl) in Subjects With Advanced Solid Tumors

CompletedNCT00708006

Human Genome Sciences Inc.Advanced Solid Tumors

Start: 2008-05-31End: 2012-01-31Updated: 2013-11-07

A Study of HGS1029 in Subjects With Relapsed or Refractory Lymphoid Malignancies

TerminatedNCT01013818

Human Genome Sciences Inc.Lymphoid Malignancies

Start: 2009-10-31End: 2011-10-31Updated: 2013-08-02